QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Posts Update on Scorpion Venom-Derived Peptide Program
PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) today issued an update regarding the second phase of its three phase, scorpion venom-derived peptide research and development program. The program consists of identifying, extracting and sequencing peptides and proteins isolated from Caribbean Blue Scorpion venom. The goal of the program is to empower PreveCeutical to produce Nature Identical™ peptide therapeutics to treat, regulate and prevent cancer progression. The company’s initial focus will target glioblastoma, a highly-aggressive form of brain cancer. PreveCeutical has started phase 2 of the program, comprised of re-designing the peptides to enhance their biostability while upholding their potency…